Syndax Pharmaceuticals Inc
Ownership
Ownership Structure
Who owns Syndax Pharmaceuticals Inc (SNDX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 89.9% of the shares are freely tradable; institutional investors hold 116.0%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 9.24 | 8,254,426 | +0.2 | 03/31/2026 |
| Kynam Capital Management, LP | 9.02 | 8,050,959 | +0.0 | 06/30/2026 |
| The Goldman Sachs Group Inc | 5.60 | 4,996,787 | -12.3 | 03/31/2026 |
| State Street Corp | 4.96 | 4,430,076 | -3.6 | 03/31/2026 |
| Bank of America Corp | 4.76 | 4,249,836 | -9.8 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.28 | 3,822,579 | +0.0 | 03/31/2026 |
| Deerfield Management Co | 4.23 | 3,779,900 | +0.0 | 03/31/2026 |
| Eversept Partners, LP | 3.13 | 2,798,210 | -3.0 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 4.16 | 3,712,463 | -1.1 | 08/31/2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 3.18 | 2,840,021 | +0.5 | 07/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Metzger Michael A | Chief Executive Officer | 484,843 | 8,581,721 $ | Jul 8, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jul 8, 2026 | Metzger Michael A | Chief Executive Officer | Sell | 32,375 | 24.24 | 784,776 |
| Jul 8, 2026 | Metzger Michael A | Chief Executive Officer | Other | 32,375 | 6.38 | 206,553 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.